Key facts
- Saluda Medical’s last known valuation is $435.0M (Dec 2025).
- It has raised $822.9M across 4 recorded rounds; the latest was Early Stage VC ($30.0M) in Oct 2025.
- 3 institutional filers report fund marks on Saluda Medical across 45 filings.
- Saluda Medical has filed 2 Form Ds with the SEC since 2023, most recently Nov 2025 ($30.0M sold to 26 investors).
- Status: Publicly Held.
- ·Post-money valuations for all 4 rounds
- ·Watchlist + deal alerts for Saluda Medical
Funding rounds
4 roundsAbout Saluda Medical
Developer of closed-loop neuron modulation devices intended to treat chronic neuropathic pain. The company's products are used for the patient's neural fingerprint to monitor and adapt the dose of electrical stimulation automatically and tailor the therapy to meet each patient's needs in real-time, enabling patients with chronic back pain to get improved treatment comfortably.
- Industry
- Therapeutic Devices
- Sector
- Healthcare
- HQ
- Bloomington, MN, United States
- Founded
- 2011
- Employees
- 483
- Website
- saludamedical.com/
- Ownership
- Publicly Held
Saluda Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Saluda Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
3 filers · latest Jun 20263 SEC-registered funds reported 45 fair-value marks on Saluda Medical between Apr 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.